In other 50 patients, corresponding to 15.6% (50/321), GPVs were detected in additional high, moderate and lower-risk BC genes: 23 GPVs (23/321 – 7.1%) were detected in high- and moderate-risk BC genes: 8 in ATM (9.6%), 6 with CHEK2 (7.2%), 4 with TP53 (4.8%), 4 with PALB2 (4.8%), 1 with RAD51C (1.2%) and 29 GPVs (29/321 – 9%) in others of unknown clinical relevance for BC. Here, CHEK2 is linked to breast cancer.